JP4402454B2 - Lnaホスホラミダイトの製造法 - Google Patents
Lnaホスホラミダイトの製造法 Download PDFInfo
- Publication number
- JP4402454B2 JP4402454B2 JP2003512245A JP2003512245A JP4402454B2 JP 4402454 B2 JP4402454 B2 JP 4402454B2 JP 2003512245 A JP2003512245 A JP 2003512245A JP 2003512245 A JP2003512245 A JP 2003512245A JP 4402454 B2 JP4402454 B2 JP 4402454B2
- Authority
- JP
- Japan
- Prior art keywords
- lna
- phosphoramidite
- cyanoethyl
- ribo
- dci
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 B[C@@](C1OC2)OC2(C*)C1OP(N(C(C)C)C(C)C)OCCC#N Chemical compound B[C@@](C1OC2)OC2(C*)C1OP(N(C(C)C)C(C)C)OCCC#N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/02—Phosphorylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Luminescent Compositions (AREA)
- Saccharide Compounds (AREA)
Description
本発明は、大量スケールのLNAホスホラミダイト(phosphoramidite)製造の高収率で速い方法に関する。
ロックド核酸(LNA;locked Nucleic Acid)の単量体およびオリゴヌクレオチドは1997年に発明され(WO 09914226)、そしてこのものはアチセンス薬物候補としての有望な結果を示している。しかしながら、該文献中には、LANベースのアンチセンス薬物の効率良い製造に必要なLNAアミダイトの最適な収率を与える大量スケールのLNAホスホラミダイト製造のための製造法はない。
本発明は、純粋なLNAホスホラミダイトの大量スケール製造のための新規な高収率で且つ速い方法を提供する。ホスホラミダイトであるLNA単量体の製造において、該ホスファイト化の段階は重要である。必要ならばまた、該ホスホラミダイトの反応性のために、精製の間のそれらの分解を避ける目的で、容易で且つ効率の良い精製法が所望される。該単量体はかなり長時間にわたる長く連続的なオリゴマー化において使用され、そこではまた不純物が該ホスホラミダイトの分解を引き起こし得るので、絶対的な純度の該アミダイトは必要である。
a)取り扱いの容易さ;
b)全ての試薬が室温で安定であること;
c)わずか0.7当量のDCIだけが必要であること;
d)ワークアップの容易さ;
e)室温での速く且つ高収率の反応;
f)コスト的に効率の良い反応;
g)高純度のアミダイトを得るのにクロマトグラフィー精製法が必須でないこと。
本明細書で使用する用語「LNA単量体」とは、国際特許出願番号WO9914226およびその後のWO0056746、WO0056748、WO0066604およびWO0228875に記載されている2',4'−架橋(特に、−O−CH2−架橋(オキシ−LNAの場合)、−S−CH2−架橋(チオ−LNAの場合)、−NR−CH2−架橋(アミノ−LNAの場合;ここで、Rは水素、C1〜6アルキル、フェニル、ベンジルなどである))を有するリボヌクレオチドを意味する。
実施例1−ホスファイト化方法
4つのホスファイト化方法を調べて、比較した:
ii)2−シアノエチル−N,N,N',N'−テトライソプロピルホスホラミダイト、1H−テトラゾール;
iii)2−シアノエチル−N,N,N',N'−テトライソプロピルホスホラミダイト、ピリジニウムトリフルオロアセテート;
iv)2−シアノエチル−N,N,N',N'−テトライソプロピルホスホラミダイト、4,5−ジシアノイミダゾール。
0.2M LNAヌクレオシド(1.0当量)の無水CH2Cl2溶液を、アルゴン下で撹拌した。1.0MのDCI(0.70当量)の無水MeCN溶液を加え、続いて2−シアノエチル−N,N,N',N'−テトライソプロピルホスホラミダイト(1.0当量)を滴下した。該反応が完結後に(これは、分析用TLC*によって追跡する)、そのものをCH2Cl2を用いて希釈し、そして飽和NaHCO3水溶液で2回、およびブラインで1回洗浄した。該有機層を乾燥し(Na2SO4)、ろ過し、そして真空下で濃縮して、無色の発泡体を得た。全てのホスホラミダイトを非常に高収率で(>95%)単離した。副生成物は、HPLC−MS、TLCまたは31P−NMRによって全く検出され得なかった(純度:ほぼ100%)。出発物質が乾燥しており且つ純粋である場合には、クロマトグラフィー精製は必要ない。
*全てのホスファイト化反応は、G−ホスホラミダイト(2)製造が完結するのに4時間まで費やすのを除いて、2時間より低くて完結した。
(1R,3R,4R,7S)−3−(4−N−ベンゾイル−5−メチルシトシン−1−イル)−1−(4,4'−ジメトキシトリチルオキシメチル)−7−ヒドロキシ−2,5−ジオキサビシクロ[2.2.1]ヘプタン(4.86g、7.2mmol)を無水CH2Cl2(40mL)に溶解し、そして4,5−ジシアノイミダゾールのMeCN(1.0M、5mL)を加えた。アルゴン下、周囲温度で撹拌した。2−シアノエチル−N,N,N',N'−テトライソプロピルホスフィノジアミダイト(2.4mL、7.2mmol)を該反応混合物に滴下した。2時間後に、該反応液をCH2Cl2(100mL)を用いて希釈し、このものを分液ろうとに移し、そして飽和NaHCO3水溶液(2×150mL)およびブライン(150mL)を用いて抽出した。該水相を合わせてCH2Cl2(100mL)を用いて抽出した。該有機層を貯蔵し、そして乾燥した(Na2SO4)。ろ過後に、該有機層を真空下で蒸発して、わずかに黄色の発泡体(6.0g、収率95%)を得た。少量の試料を、クロマトグラフィー精製した物質との比較のために取り出した。該生成物をドライカラムバキュームクロマトグラフィー(径10cm;5%容量比のEt3Nのn−ヘプタン溶液を用いて前処理したシリカゲル;0→70%容量比のEtOAcのn−ヘプタンを使用)によって精製した。3を含有する選択した画分を合わせて、真空下で蒸発して、無色の発泡体(5.3g、収率84%)を得た。
(1R,3R,4R,7S)−7−(2−シアノエトキシ(ジイソプロピルアミノ)ホスフィノキシ)−1−(4,4'−ジメトキシトリチルオキシメチル)−3−(チミン−1−イル)−2,5−ジオキサビシクロ[2.2.1]ヘプタン(1)
31P-NMR (CDCl3, 121.49 MHz): δ 150.0 (s), 149.3 (s)。
MS (ES): m/z(C41H49N4O9Pとして計算)[M+H]+: 計算値:773.3、実測値:773.1。
RP HPLC: RT = 5.89分,6.19分。
31P-NMR (CDCl3, 121.49 MHz): δ 150.2 (s), 149.2 (s)。
MS (ES): m/z(C45H54N7O9Pとして計算)[M+H]+: 計算値:868.4、実測値:868.0。
RP HPLC: RT = 5.52分,5.72分。
31P-NMR (CDCl3, 121.49 MHz): δ 150.5 (s), 150.5 (s)。
MS (ES): m/z(C48H54N5O9Pとして計算)[M+H]+: 計算値:876.4、実測値:876.2。
RP HPLC: RT = 7.67分,8.13分。
(HPLC溶媒勾配: 0.0-0.5分 95%B、0.5-2.0分 95%→100%B、2.0-7.0分 100%B、7.0-7.5分 100%→95%B、7.5-12.0分 95%B)。
31P-NMR (CDCl3, 121.49 MHz): δ 150.1 (s), 149.7 (s)。
MS (ES): m/z(C48H52N7O8Pとして計算)[M+H]+: 計算値:886.3、実測値:886.0。
RP HPLC: RT = 6.65分,6.82分。
31P-NMR (CDCl3, 121.49 MHz): δ 149.8 (s), 149.6 (s)。
MS (ES):m/z(C42H52N5O8Pとして計算)[M+H]+: 計算値:786.3、実測値:786.2。
RP HPLC: RT = 5.87分,6.26分。
31P-NMR (CDCl3, 121.49 MHz): δ 150.9 (s), 150.6 (s)。
MS (ES):m/z(C41H49N4O9Pとして計算)[M+H]+: 計算値:773.3、実測値:773.1。
RP HPLC: RT = 6.06分,6.44分。
Claims (8)
- LNAホスホラミダイトの製造方法であって、
4,5−ジシアノイミダゾール(DCI)の存在下での、2−シアノエチル−N,N,N',N'−テトライソプロピルホスホラミダイトを用いる、2 ’ ,4 ’ −架橋を有するLNA単量体の3'−OH基のホスファイト化を含み、そして、
該LNA単量体およびDCIの間のモル比は、1:0.7〜1:1の範囲である、
該方法。 - 該2 ’ ,4 ’ −架橋は、−O−CH 2 −架橋、−S−CH 2 −架橋、または−NR−CH 2 −架橋であり、ここで、Rは、水素、C 1〜6 アルキル、フェニル、およびベンジルからなる群から選ばれる、請求項1記載の方法。
- 最大1つの沈降工程を含む、請求項1または2のいずれか記載の方法。
- LNA単量体および2−シアノエチル−N,N,N',N'−テトライソプロピルホスホラミダイトの間のモル比は、1:0.9〜1:1の範囲である、請求項1〜3のいずれか1つ記載の方法。
- ホスファイト化は0.5〜4時間で進行することができる、請求項1〜4のいずれか1つ記載の方法。
- LNA単量体は、グアニン、チミン、シトシン、メチルシトシン、ウラシル、またはアデニンから選ばれる核酸塩基を有する、請求項1〜5のいずれか1つ記載の方法。
- LNA単量体構造は、オキシ−β−D−リボ−LNA、チオ−β−D−リボ−LNA、アミノ−β−D−リボ−LNA、オキシ−α−L−リボ−LNA、チオ−α−L−リボ−LNA、またはアミノ−α−L−リボ−LNAから選ばれる、請求項1〜6のいずれか1つ記載の方法。
- 該LNA単量体およびDCIの間のモル比は、1:0.7である、請求項1〜7のいずれか1つ記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200101095 | 2001-07-12 | ||
PCT/DK2002/000488 WO2003006475A2 (en) | 2001-07-12 | 2002-07-12 | Method for preparation of lna phosphoramidites |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004536125A JP2004536125A (ja) | 2004-12-02 |
JP2004536125A5 JP2004536125A5 (ja) | 2006-01-05 |
JP4402454B2 true JP4402454B2 (ja) | 2010-01-20 |
Family
ID=8160624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003512245A Expired - Lifetime JP4402454B2 (ja) | 2001-07-12 | 2002-07-12 | Lnaホスホラミダイトの製造法 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1409497B1 (ja) |
JP (1) | JP4402454B2 (ja) |
AT (1) | ATE287413T1 (ja) |
AU (1) | AU2002328792A1 (ja) |
DE (1) | DE60202681T2 (ja) |
DK (1) | DK1409497T3 (ja) |
WO (1) | WO2003006475A2 (ja) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2264172T (pt) | 2002-04-05 | 2017-12-06 | Roche Innovation Ct Copenhagen As | Compostos oligoméricos para a modulação da expressão do hif-1α. |
US7713738B2 (en) | 2003-02-10 | 2010-05-11 | Enzon Pharmaceuticals, Inc. | Oligomeric compounds for the modulation of survivin expression |
WO2004069991A2 (en) | 2003-02-10 | 2004-08-19 | Santaris Pharma A/S | Oligomeric compounds for the modulation of survivin expression |
ATE443765T1 (de) | 2003-03-21 | 2009-10-15 | Santaris Pharma As | Analoga kurzer interferierender rna (sirna) |
AU2004303464B2 (en) | 2003-12-23 | 2009-10-01 | Santaris Pharma A/S | Oligomeric compounds for the modulation of BCL-2 |
AU2005304110B2 (en) | 2004-11-09 | 2009-06-11 | Enzon Pharmaceuticals, Inc. | LNA oligonucleotides and the treatment of cancer |
US9447138B2 (en) | 2004-11-09 | 2016-09-20 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
NZ555644A (en) | 2004-11-09 | 2009-04-30 | Santaris Pharma As | Potent LNA oligonucleotides for the inhibition of HIF-1A expression |
ES2548240T3 (es) | 2005-12-01 | 2015-10-15 | Pronai Therapeutics, Inc. | Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas |
JP5244087B2 (ja) | 2006-03-23 | 2013-07-24 | サンタリス ファーマ アー/エス | 低分子内部セグメント化干渉rna |
CA3042781C (en) | 2006-04-03 | 2021-10-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
EP3502255A1 (en) | 2006-04-03 | 2019-06-26 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition |
US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
EP2126079A1 (en) | 2007-03-22 | 2009-12-02 | Santaris Pharma A/S | Rna antagonist compounds for the inhibition of apo-b100 expression |
EP2173373B1 (en) | 2007-06-06 | 2020-04-15 | Sarepta Therapeutics, Inc. | Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease |
WO2009027978A1 (en) | 2007-08-30 | 2009-03-05 | Hadasit Medical Research Services & Development Ltd. | NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS |
EP2623599B1 (en) | 2007-10-04 | 2019-01-02 | Roche Innovation Center Copenhagen A/S | Micromirs |
US9211537B2 (en) | 2007-11-07 | 2015-12-15 | The University Of British Columbia | Microfluidic device and method of using same |
WO2009109665A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
ES2541442T3 (es) | 2008-08-01 | 2015-07-20 | Roche Innovation Center Copenhagen A/S | Modulación mediada por microARN de factores estimulantes de colonias |
ES2599979T3 (es) | 2009-04-24 | 2017-02-06 | Roche Innovation Center Copenhagen A/S | Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón |
WO2011009697A1 (en) | 2009-07-21 | 2011-01-27 | Santaris Pharma A/S | Antisense oligomers targeting pcsk9 |
WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
GB201012418D0 (en) | 2010-07-23 | 2010-09-08 | Santaris Pharma As | Process |
EP2609198B8 (en) | 2010-08-24 | 2018-03-28 | Sirna Therapeutics, Inc. | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER |
EP2914742A1 (en) | 2012-11-05 | 2015-09-09 | Pronai Therapeutics, Inc. | Methods of using biomarkers for the treatment of cancer by modulation of bcl2!expression |
EP2943570B1 (en) | 2013-01-14 | 2018-01-03 | Pierfrancesco Tassone | Inhibitors of mirnas 221 and 222 for anti-tumor activity in multiple myeloma |
PT3013959T (pt) | 2013-06-27 | 2020-02-04 | Roche Innovation Ct Copenhagen As | Oligómeros antissentido e conjugados dirigidos para pcsk9 |
WO2015075166A1 (en) | 2013-11-22 | 2015-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of a bacterial infection |
EP3099798B1 (en) | 2014-01-29 | 2018-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Oligonucleotides and methods for inhibiting or reducing bacterial biofilms |
GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
AU2015318782A1 (en) | 2014-09-18 | 2017-04-06 | The University Of British Columbia | Allele-specific therapy for Huntington Disease haplotypes |
KR102620328B1 (ko) | 2014-10-03 | 2024-01-02 | 콜드스프링하버러보러토리 | 핵 유전자 산출량의 표적화 증강 |
US20190055550A1 (en) * | 2015-08-24 | 2019-02-21 | Roche Innovation Center Copenhagen A/S | LNA-G Process |
AU2016334804B2 (en) | 2015-10-09 | 2022-03-31 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
AU2016370653A1 (en) | 2015-12-14 | 2018-06-21 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of Autosomal Dominant Mental Retardation-5 and Dravet Syndrome |
US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
US20220354888A1 (en) | 2016-08-03 | 2022-11-10 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
EP4303321A2 (en) | 2017-08-25 | 2024-01-10 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
WO2019076919A1 (en) | 2017-10-17 | 2019-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | COMBINED TREATMENT OF CYSTIC FIBROSIS |
WO2021005223A1 (en) | 2019-07-10 | 2021-01-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of epilepsy |
IT201900017234A1 (it) | 2019-09-25 | 2021-03-25 | Int Centre For Genetic Engineering And Biotechnology | Anti-miRNA per il trattamento del leiomioma |
WO2021074657A1 (en) | 2019-10-17 | 2021-04-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination treatment for cystic fibrosis |
IL292286A (en) * | 2019-10-18 | 2022-06-01 | Daiichi Sankyo Co Ltd | Production method for bicyclic phosphoramidite |
US20230018780A1 (en) * | 2019-11-13 | 2023-01-19 | Nippon Shinyaku Co., Ltd. | Method for producing oligonucleic acid compound |
WO2021099394A1 (en) | 2019-11-19 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antisense oligonucleotides and their use for the treatment of cancer |
WO2021231107A1 (en) | 2020-05-11 | 2021-11-18 | Stoke Therapeutics, Inc. | Opa1 antisense oligomers for treatment of conditions and diseases |
WO2022011262A1 (en) | 2020-07-10 | 2022-01-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating epilepsy |
KR20230118076A (ko) * | 2020-12-11 | 2023-08-10 | 야마사 쇼유 가부시키가이샤 | 시토신형 가교형 뉴클레오시드 아미다이트 결정 및 그 제조 방법 |
AU2022219031A1 (en) | 2021-02-12 | 2023-09-07 | Merand Pharmaceuticals, Inc. | Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders |
WO2022200633A1 (en) | 2021-03-26 | 2022-09-29 | Neumirna Therapeutics Aps | Microrna-27b inhibitors |
AU2022245292A1 (en) | 2021-03-26 | 2023-10-12 | Neumirna Therapeutics Aps | Microrna-134 inhibitors |
WO2022254021A1 (en) | 2021-06-04 | 2022-12-08 | Neumirna Therapeutics Aps | Antisense oligonucleotides targeting adenosine kinase |
CA3229568A1 (en) | 2021-08-17 | 2023-02-23 | Korea Advanced Institute Of Science And Technology | Antisense oligonucleotide targeting cav3.1 gene and uses thereof |
CA3228833A1 (en) | 2021-08-19 | 2023-02-23 | Neumirna Therapeutics Aps | Antisense oligonucleotides targeting adenosine kinase |
WO2023152369A1 (en) | 2022-02-14 | 2023-08-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis |
WO2024017990A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating chronic pain disorders |
EP4332239A1 (en) | 2022-08-30 | 2024-03-06 | Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. | Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4800197A (en) * | 1996-10-15 | 1998-05-11 | Nexstar Pharmaceuticals, Inc. | Improved coupling activators for oligonucleotide synthesis |
-
2002
- 2002-07-12 JP JP2003512245A patent/JP4402454B2/ja not_active Expired - Lifetime
- 2002-07-12 EP EP02764561A patent/EP1409497B1/en not_active Expired - Lifetime
- 2002-07-12 WO PCT/DK2002/000488 patent/WO2003006475A2/en active IP Right Grant
- 2002-07-12 DE DE60202681T patent/DE60202681T2/de not_active Expired - Lifetime
- 2002-07-12 AT AT02764561T patent/ATE287413T1/de not_active IP Right Cessation
- 2002-07-12 DK DK02764561T patent/DK1409497T3/da active
- 2002-07-12 AU AU2002328792A patent/AU2002328792A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003006475A2 (en) | 2003-01-23 |
JP2004536125A (ja) | 2004-12-02 |
DK1409497T3 (da) | 2005-05-30 |
ATE287413T1 (de) | 2005-02-15 |
WO2003006475A3 (en) | 2004-02-26 |
EP1409497A2 (en) | 2004-04-21 |
EP1409497B1 (en) | 2005-01-19 |
DE60202681T2 (de) | 2006-01-12 |
DE60202681D1 (de) | 2005-02-24 |
AU2002328792A1 (en) | 2003-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4402454B2 (ja) | Lnaホスホラミダイトの製造法 | |
US7153954B2 (en) | Method for preparation of LNA phosphoramidites | |
US6090932A (en) | Method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement | |
EP0219342B1 (en) | Method and reagents for in vitro oligonucleotide synthesis | |
EP2567964B1 (en) | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | |
JP5228002B2 (ja) | リボヌクレオチド又はリボヌクレオチド誘導体の製造方法 | |
EP1792909A1 (en) | Synthesis of polynucleotides | |
JP7484951B2 (ja) | オリゴヌクレオチドの製造方法 | |
JP2794461B2 (ja) | ホスホアミダイト化合物及びそれを用いたオリゴリボヌクレオチドの固相合成法 | |
JP2003514766A (ja) | 活性剤としてルイス酸を用いるオリゴヌクレオチド合成 | |
EP1317466A2 (en) | Synthons for oligonucleotide synthesis | |
Tsurusaki et al. | Development of a new synthetic method for oligodeoxynucleotides using 3′-H-phosphonamidate derivatives | |
US20070172925A1 (en) | Ribonucleic acid compound and method of liquid-phase synthesis of oligonucleic acid compound | |
WO2006095739A1 (ja) | リボヌクレオシドの2’水酸基の脱保護方法 | |
US5756707A (en) | Method of making 2'-O-alkyl pyrimidine ribonucleosides | |
JPH06135988A (ja) | ヌクレオシド誘導体 | |
JP2024511706A (ja) | ヌクレオシドホスホロアミダイトのn-環外アミノ環式炭化水素保護基の急速脱保護 | |
WO2021080021A1 (ja) | オリゴヌクレオチドを製造する方法 | |
Tsukamoto et al. | Strategies useful for the chemical synthesis of oligonucleotides and related compounds | |
JPH06135989A (ja) | ヌクレオシド誘導体 | |
JPH0680071B2 (ja) | ホスホルアミダイト化合物及びその製造法 | |
WO2014022839A1 (en) | Exocylic nitrogen atom protected nucloside and method for producing and using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050707 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050707 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090519 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090812 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090817 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20090817 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090817 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090819 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090908 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091020 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091029 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4402454 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121106 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121106 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131106 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |